---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-031303"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T14:21:52.466092+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amylyx reports Q4 net loss of $37.5M, cash runway extended through 2026 after $65.5M raise

## Summary
- Net loss for Q4 2024 was $37.5M ($0.55 per share); FY2024 net loss of $301.7M ($4.43 per share).
- Cash, equivalents & short-term investments were $176.5M at Dec 31, 2024; plus $65.5M raised in Jan 2025.
- Phase 3 LUCIDITY trial of avexitide in PBH recruiting; topline data expected first half 2026.
- Appointed Dan Monahan as Chief Commercial Officer to lead commercialization strategy.
- R&D expenses fell to $22.9M in Q4 2024 from $44.9M in Q4 2023; SG&A fell to $17.1M from $52.2M.

## SEC filing metadata
- accession: 0000950170-25-031303
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/0000950170-25-031303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/amlx-20250304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-031303
- JSON: https://secwatch.observer/filing/0000950170-25-031303.json
- Plain text: https://secwatch.observer/filing/0000950170-25-031303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.